Home › Research › Prevention and risk
Cognitive benefits of hearing intervention vary by risk of cognitive decline: A secondary analysis of the ACHIEVE trial
James Russell Pike, Alison Huang, Nicholas Simon Reed, Michelle L. Arnold, Theresa Hnath Chisolm, David J. Couper, Jennifer A. Deal, Nancy W. Glynn et al.. Alzheimer s & Dementia, 2025-05-01
Topic: Risk, prevention and care in population studies
Plain-language summary
Among ACHIEVE participants in the top quartile of predicted risk, 3-year cognitive decline in the hearing intervention was 61.6% (95% confidence interval [CI]: 33.7%-94.1%) slower than the control. The effect of hearing intervention on reducing 3-year cognitive decline was greatest among individuals with multiple baseline risk factors associated with faster cognitive decline. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03243422 HIGHLIGHTS: The Aging and Cognitive Health Evaluation in Elders (ACHIEVE) trial tested the effect of hearing intervention on cognitive decline. Participants were recruited from the Atherosclerosis Risk in Communities (ARIC) cohort or de novo from the local community. A 48% reduction in cognitive decline was observed in ARIC cohort participants. In this secondary analysis, there was an interaction between hearing intervention and predicted risk of cognitive decline. Among participants in the top quartile of predicted risk of cognitive decline, hearing intervention slowed cognitive decline by 62%.
What this study adds
Evidence grade: Moderate
The record lists 2,692 participants. This secondary analysis of the ACHIEVE trial found that hearing intervention slowed 3-year cognitive decline by about 62% among participants in the top quartile of predicted risk of cognitive decline. Reported effect size: 61.6%; 33.7%; 94.1%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Pike, J. R., Huang, A., Reed, N. S., Arnold, M. L., Chisolm, T. H., Couper, D. J., et al. (2025). Cognitive benefits of hearing intervention vary by risk of cognitive decline: A secondary analysis of the ACHIEVE trial. Alzheimer s & Dementia. https://doi.org/10.1002/alz.70156
Vancouver
Pike JR, Huang A, Reed NS, Arnold ML, Chisolm TH, Couper DJ, et al. Cognitive benefits of hearing intervention vary by risk of cognitive decline: A secondary analysis of the ACHIEVE trial. Alzheimer s & Dementia. 2025. doi:10.1002/alz.70156. PMID: 40369891.
BibTeX
@article{pike2025-40369891,
author = {Pike, James Russell and Huang, Alison and Reed, Nicholas Simon and Arnold, Michelle L. and Chisolm, Theresa Hnath and Couper, David J. and Deal, Jennifer A. and Glynn, Nancy W. and others},
title = {{Cognitive benefits of hearing intervention vary by risk of cognitive decline: A secondary analysis of the ACHIEVE trial}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz.70156},
pmid = {40369891},
url = {https://doi.org/10.1002/alz.70156}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Among ACHIEVE participants in the top quartile of predicted risk, 3-year cognitive decline in the hearing intervention was 61.6% (95% confidence interval [CI]: 33.7%-94.1%) slower than the control.
- The effect of hearing intervention on reducing 3-year cognitive decline was greatest among individuals with multiple baseline risk factors associated with faster cognitive decline.
- TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03243422 HIGHLIGHTS: The Aging and Cognitive Health Evaluation in Elders (ACHIEVE) trial tested the effect of hearing intervention on cognitive decline.
- Participants were recruited from the Atherosclerosis Risk in Communities (ARIC) cohort or de novo from the local community.
- A 48% reduction in cognitive decline was observed in ARIC cohort participants.
Why it matters
This secondary analysis of the ACHIEVE trial found that hearing intervention slowed 3-year cognitive decline by about 62% among participants in the top quartile of predicted risk of cognitive decline. The effect was greatest in people with multiple baseline risk factors for faster cognitive decline.
New to this subject? Start with our plain-English guide: Prevention →
Study details
- Participants2,692
- Effect size61.6%; 33.7%; 94.1%
- Evidence strengthModerate
How this study scored 58/100
Published in a peer-reviewed journal. Scored zero for study design and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 3 / 4 | 2,692 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 16 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 5.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 4 / 6 | Cited 9.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 2 / 4 | Cited 16 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Frank Robert Lin: h-index 75 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Johns Hopkins University: institution h-index 2,306 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 12 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40369891) |
| Free to read | 2 / 2 | Free to read |
| Total | 58 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 16.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Prevention and risk from nearby years
Also tagged “controlled”
1,116 studies in the library carry the topic tag “controlled”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,116 tagged studies.